Trial Profile
A multicenter, retrospective study evaluating the efficacy of alectinib or crizotinib ALK-rearranged non-small cell lung cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2016
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Oct 2016 New trial record